Search | Clinical Trials Finder

Conditions: Infections, Bacterial
Interventions: Gepotidacin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Covid19
Interventions: Sotrovimab (Gen1), Sotrovimab (Gen2); Biological
Lead sponsor: Vir Biotechnology, Inc.; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 18
States / cities: Anniston, Alabama • Bakersfield, California • Northridge, California + 12 more

Conditions: B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Interventions: Alemtuzumab; Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 7
States / cities: La Jolla, California • La Verne, California • Aurora, Colorado + 4 more

Conditions: Body Weight Changes, Overweight
Interventions: Group weight loss program, Group weight loss program plus use of the Senseware Armband, Use of the senseware armband alone program; Behavioral · Other · Device
Lead sponsor: University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 197 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Healthy Volunteer
Interventions: ABBV-1451, Placebo; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Type 2 Diabetes
Interventions: Placebo, Survodutide; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 89
States / cities: Birmingham, Alabama • Gilbert, Arizona • Paradise Valley, Arizona + 81 more

Conditions: Peripheral Artery Disease
Interventions: Home-based exercise intervention; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Chicago, Illinois • Minneapolis, Minnesota • New York, New York

Conditions: Infertility, Recurrent Pregnancy Loss
Interventions: PGD, PGD; Genetic · Procedure
Lead sponsor: Reprogenetics; Industry
Eligibility: 32 Years to 42 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 4
States / cities: Beverly Hills, California • Highland Park, Illinois • Livingston, New Jersey + 1 more

Conditions: Cystic Fibrosis
Interventions: Ivacaftor 25 mg/75 mg, Ivacaftor 75 mg/150 mg, Ivacaftor 150 mg or 250 mg, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 13
States / cities: Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 9 more

Conditions: Alcoholic Hepatitis
Interventions: Not listed
Lead sponsor: Indiana University; Other
Eligibility: 21 Years and older
Enrollment: 454 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 2
States / cities: Rochester, Minnesota • Richmond, Virginia

Conditions: HIV Infections
Interventions: Part A, C and D: VH3739937 500 mg, Part A: VH3739937 100 mg, Part A and C: Placebo, Part B: Treatment A, Part B: Treatment B, Part B: Treatment C, Part B: Treatment D, Part B: Treatment E, Part D: Probe cocktail; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Weight Management
Interventions: GS-4571, Placebo, Omeprazole; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 134 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Miami, Florida • San Antonio, Texas • Salt Lake City, Utah

Conditions: Healthy Volunteers
Interventions: KarXT, KarX-EC, Placebo, Omeprazole; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 19 Years to 90 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Anaheim, California

Conditions: CoronaVirus Disease-2019 (COVID-19)
Interventions: ABBV-47D11, Placebo for ABBV-47D11, ABBV-2B04, Placebo for ABBV-2B04; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 11
States / cities: Glendale, California • Cutler Bay, Florida • Miami, Florida + 8 more

Conditions: CLL, SLL
Interventions: Ofatumumab, High-Dose Methylprednisolone, Alemtuzumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: HIV-1
Interventions: F/TAF, 3rd ARV agent, Boosted PIs; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 4
States / cities: Los Angeles, California • Aurora, Colorado • Philadelphia, Pennsylvania + 1 more

Conditions: Acute Myeloid Leukemia
Interventions: Venetoclax, Cytarabine, Idarubicin, Intrathecal Triple Therapy, Azacitidine; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 2 Years to 20 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 3
States / cities: Palo Alto, California • Chapel Hill, North Carolina • Memphis, Tennessee

Conditions: Multiple Myeloma, Fatigue
Interventions: AYO light glasses (Experimental), AYO light glasses (Comparator); Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2022
U.S. locations: 3
States / cities: Hackensack, New Jersey • New York, New York

Conditions: Healthy Volunteers
Interventions: BMS-986435; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy
Interventions: ALS-008176, Placebo, Moxifloxacin; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy Volunteer
Interventions: ABBV-722, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Cypress, California • Grayslake, Illinois

Conditions: Diabetes Mellitus, Type 2, Insulin Resistance
Interventions: Egg breakfast, Egg breakfast with high saturated fat, Cereal breakfast, Cereal breakfast with high saturated fat; Behavioral
Lead sponsor: Texas Tech University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Acromegaly
Interventions: ONO-5788, ONO-5788 Placebo, Octreotide; Drug
Lead sponsor: Ono Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: HIV
Interventions: CD4BS CH505M5 Pr-NP1, CH505TF chTrimer, 3M-052-AF (labeled as AP 60-702), Aluminum Hydroxide Suspension (Alum), ACU-026-001-1 (labeled as empty LNP); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Birmingham, Alabama • Atlanta, Georgia • Nashville, Tennessee

Search by objective public record fields.

Pharmacokinetics (PK) Study of Gepotidacin (GSK2140944) in Adult Subjects With Varying Degrees of Hepatic Impairment and in Matched Control Subjects With Normal Hepatic Function

Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19

Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia

Lifestyle Education for Activity and Nutrition for a Leaner You

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Ascending Doses of ABBV-1451 Infusions and Injections in Healthy Adult Participants

A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

Patient Centered Home Exercise Program for Peripheral Artery Disease

Preimplantation Genetic Diagnosis Using Blastocyst Biopsy and Array CGH

Safety Study of Ivacaftor in Subjects With Cystic Fibrosis

Alcoholic Hepatitis: A Multicenter, Observational Study by the TREAT Consortium

VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)

Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)

A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Xanomeline With Trospium Chloride Versus KarXT in Healthy Adult and Elderly Participants of Japanese Ethnicity and to Assess the Effect of Omeprazole on the PK of Xanomeline With Trospium Chloride in Healthy Adult Participants

Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-2B04 Given Alone and in Combination Moves Through the Body of Adult Participants With Coronavirus Disease 2019 (COVID-19)

Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL

Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen

Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage

Treating Cancer-Related Fatigue Through Systematic Light Exposure (Light for Fatigue Study)

A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult Participants

Study to Evaluate the Effect of ALS-008176 on Cardiac Repolarization Interval in Healthy Participants

A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants

Determining Dietary Pattern Accompanying Egg Intake Using Remote Food Photography Method

A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers

A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum